

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mediwelcome Healthcare Management & Technology Inc.

麥迪衛康健康醫療管理科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2159)

PROFIT WARNING

This announcement is made by Mediwelcome Healthcare Management & Technology Inc. (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 (the “**Period**”), the Group is expected to record an increase in the net loss of approximately 310% comparing with the corresponding period last year whereas the unaudited consolidated net loss recorded in the corresponding period last year was approximately RMB4.0 million.

In the opinion of the Board, the increase in the net loss was primarily attributable to (i) the increase in listing expenses when compared with the corresponding period last year since the Group listed in 2021, which is approximately RMB11.3 million for the Period as compared with approximately RMB3.5 million for the six months ended 30 June 2020; and (ii) the grant of a total of 15,170,000 restricted share units to 31 eligible participants under the restricted share units scheme by the Group on 25 June 2021 in recognition of their contributions to the development of the Group and to incentivise them to further promote the development of the Company, which was recognised as share-based compensation expenses of approximately RMB9 million for the Period. The Group did not record any share-based compensation expenses during the corresponding period in 2020.

The Group is still in the process of finalising the interim results for the Period. The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group for the Period, which has not been reviewed by the auditor and the audit committee of the Company and may be subject to further adjustment based on further updated information. The actual financial results for the Period may be different from what is disclosed in this announcement. The shareholders of the Company and potential investors are advised to read carefully the interim results of the Group for the Period, which is expected to be announced in late August 2021.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Mediwelcome Healthcare Management & Technology Inc.
Shi Wei
Chairman and Executive Director

Hong Kong, 3 August 2021

As at the date of this announcement, the executive Directors are Mr. Shi Wei, Mr. Yang Weimin, Mr. Wang Liang, Mr. He Jiyong, Mr. Wang Wei and Mr. Sui Huijun; the non-executive Directors are Ms. Zhang Yitao and Mr. Liu Xia; and the independent non-executive Directors are Mr. Song Ruilin, Mr. Fei John Xiang, Mr. David Zheng Wang and Mr. Yang Xiaoxi.